Abstract

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I8/500

[1] 中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会. 华法林抗凝治疗的中国专家共识[J]. 中华内科杂志, 2013, 52(1): 76-82.
[2] 那开宪, 余平, 张桂云. 应重视华法林治疗过程中的影响因素[J]. 中国临床医生杂志, 2016，44(5): 3-6.
[3] Sienkiewicz B. Comparison of clinical pharmacology of voriconazole and posaconazole[J]. Contemporary Oncology, 2016, 20(5):365-373.
[4] Luong M L, Al-Dabbagh M, Groll A H, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis[J]. Journal of Antimicrobial Chemotherapy, 2016, 71(7):1786-1799.
[5] 兰安杰，丁春雷，罗静，等，氟康唑注射液与华法林片合用致药物性肝损伤及凝血功能异常1 例[J].中国药物警戒2011，8(1)：61-62.
[6] Motta I, Calcagno A, Baietto L, et al. Erratum: A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19 patient[J]. Le Infezioni in Medicina Rivista Periodica Di Eziologia Epidemiologia Diagnostica Clinica E Terapia Delle Patologie Infettive, 2016, 24(1):89.
[7] Sumonrat C, Jantararoungtong T, Chitasombat M N, et al. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis [J]. Drug Metabolism & Pharmacokinetics, 2016, 31(2):117-122.
[8] Huurneman L J, Neely M, Veringa A, et al. Pharmacodynamics of Voriconazole in Children: Further Steps Along the Path to True Individualized Therapy[J]. Antimicrobial Agents & Chemotherapy, 2016, 60(4): 2336-2342.
[9] Benjamin L D, Jolliff J, Munoz A, et al. Cross-reactivity between voriconazole, fluconazole and itraconazole[J]. Journal of Clinical Pharmacy & Therapeutics, 2016, 41(5):566-567.
[10] 赵明, 梁良，张亚同，等, 唑类抗真菌药物对华法林抗凝活性影响的临床分析和比较[J].中国药物警戒，2016, 13(2): 111-114.
[11] Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin[J]. Biol Pharm Bull, 2014, 37(12):1990-1993.
[12] Momary K M, Shapiro N L, Viana M A, et al. Factors influencing warfarin dose requirements in African-Americans[J]. Pharmacoge-nomics, 2017, 8(11):1535-1544.
[13] Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort[J]. Pharmacogenomics, 2016, 12(1):125-134.
[14] Ross S, Paré G. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran[J]. Pharm-acogenomics, 2016, 14(13):1565-1572.
[15] 张亚同，付春毅，李铮，等.华法林常规剂量方案下抗凝效果和相关因素分析[J].中国药物警戒，2015, 12(9): 567-569.
[16] Uehara S, Inoue T, Utoh M, et al. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus)[J]. Xenobiotica, 2016, 46(2):1-6.
[17] Mayet A Y. Patient adherence to warfarin therapy and its impact on anticoagulation control[J]. Saudi Pharmaceutical Journal, 2016, 24(1): 29-34.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913.
[2]	QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
[3]	LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
[4]	ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789.
[5]	LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793.
[6]	LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569.
[7]	YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
[8]	LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285.
[9]	ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192.
[10]	LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
[11]	SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414.
[12]	ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024.
[13]	YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.
[14]	SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899.
[15]	WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.